Novo Nordisk Aktie

66,00 EUR +2,69 EUR +4,25 %

18:27:53

STU

65,62 EUR +1,76 EUR +2,76 %

17:50:05

GVIE

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.283,82 Mrd. EUR

KGV27,53Div. Rendite1,83%

WKNA3EU6F

ISINDK0062498333

SymbolNONOF

Novo Nordisk Aktien News

Sortieren:Datum Meistgelesen

26.06.24GlobeNewswireNovo Nordisk stops the ocedurenone CLARION-CKD trial and recognises impairment loss

24.06.24GlobeNewswireNovo Nordisk announces 4.1 billion USD investment to expand US manufacturing capacity adline

24.06.24GlobeNewswireNovo Nordisk A/S - share repurchase programme

18.06.24GlobeNewswireNovo Nordisk announces presentation of data from key semaglutide clinical trials in diabetes, obesity and chronic kidney disease at the 84th Scientific Sessions of the American Diabetes Association

17.06.24GlobeNewswireNovo Nordisk A/S - share repurchase programme

10.06.24GlobeNewswireNovo Nordisk A/S - share repurchase programme

03.06.24GlobeNewswireNovo Nordisk A/S - share repurchase programme

27.05.24GlobeNewswireNovo Nordisk A/S - share repurchase programme

17.05.24GlobeNewswireNovo Nordisk A/S - share repurchase programme

15.05.24GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

13.05.24GlobeNewswireNovo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A in th

08.05.24GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

06.05.24GlobeNewswireTrading in Novo Nordisk shares by board members, executives and associated persons

06.05.24GlobeNewswireNovo Nordisk A/S - share repurchase programme

06.05.24GlobeNewswireNovo Nordisk A/S purchases B shares worth DKK 5,428 million from Novo Holdings A/S under the 2024 share repurchase programme

03.05.24GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

02.05.24GlobeNewswireNovo Nordisk's sales increased by 22% in Danish kroner and by 24% at constant exchange rates to DKK 65.3 billion in the first three months of 2024

01.05.24GlobeNewswireNovo Nordisk A/S - share repurchase programme

26.04.24GlobeNewswireNovo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 26 April 2024

24.04.24GlobeNewswireNovo Nordisk A/S - Articles of Association, April 2024

24.04.24GlobeNewswireNovo Nordisk A/S – Reduction of the share capital

22.04.24GlobeNewswireNovo Nordisk A/S - share repurchase programme

15.04.24GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

15.04.24GlobeNewswireNovo Nordisk A/S - share repurchase programme

08.04.24GlobeNewswireNovo Nordisk A/S - share repurchase programme

02.04.24GlobeNewswireNovo Nordisk A/S - share repurchase programme

25.03.24GlobeNewswireNovo Nordisk A/S - share repurchase programme

25.03.24GlobeNewswireNovo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease

25.03.24GlobeNewswireNovo Nordisk A/S - Articles of Association 2024

21.03.24GlobeNewswireAwiqli® (once-weekly basal insulin icodec) recommended for approval for the treatment of diabetes by the European regulatory authorities

21.03.24GlobeNewswireResolutions from the Annual General Meeting of Novo Nordisk A/S

18.03.24GlobeNewswireNovo Nordisk A/S - share repurchase programme

11.03.24GlobeNewswireNovo Nordisk A/S - share repurchase programme

08.03.24GlobeNewswireWegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease

07.03.24GlobeNewswireHighlights to be presented at Novo Nordisk’s Capital Markets Day 2024

05.03.24GlobeNewswireNovo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial

04.03.24GlobeNewswireNovo Nordisk A/S - share repurchase programme

26.02.24GlobeNewswireNovo Nordisk A/S - share repurchase programme

21.02.24GlobeNewswireNotice for the Annual General Meeting of Novo Nordisk A/S

19.02.24GlobeNewswireNovo Nordisk A/S – Share repurchase programme

Novo Nordisk News

Novo Nordisk News: auf dieser Seite finden Sie alle Novo Nordisk News und Nachrichten zur Novo Nordisk Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novo Nordisk News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novo Nordisk News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.